Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence.
paper
Cited
Public
Unavailable
- Authors
- Berrettini, Wade H; Wileyto, E Paul; Epstein, Leonard; Restine, Stephanie; Hawk, Larry; Shields, Peter; Niaura, Ray; Lerman, Caryn
- Year
- 2007
- Journal
- Biological psychiatry
- PMID
- 16876132
- DOI
- 10.1016/j.biopsych.2006.04.030
BACKGROUND: Although bupropion is efficacious for smoking cessation, only a minority of smokers are able to quit. Pharmacogenetic research may improve treatment outcomes through discovery of DNA sequences predictive of successful pharmacotherapy for subgroups of smokers. We investigated variants in the catechol-O-methyltransferase (COMT) gene in a smoking cessation trial of bupropion. METHODS: A double-blind, placebo-controlled, 10-week trial of bupropion and counseling (with a 6-month follow-up period) was conducted at two university-based smoking cessation research programs. Abstinence was biochemically verified at the end of treatment and at 6 months after the target quit date. RESULTS: At the end of the treatment phase, statistically significant interaction effects indicated that COMT haplotypes of two SNPs (rs737865 and rs165599) predicted the efficacy of bupropion compared with placebo. This interaction effect was attenuated at 6-month follow-up. CONCLUSIONS: COMT haplotypes at rs737865 and rs165599 may predict a favorable outcome for bupropion treatment for smoking cessation. European-American smokers with a G allele at both SNPs may not benefit from bupropion treatment. Small numbers of some COMT haplotypes limit interpretation of response. If study findings are confirmed in additional large studies, COMT genotyping could be applied to identify likely responders to bupropion treatment for smoking cessation.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Nicotine Abuse and Neurodegeneration: Novel Pharmacogenetic Targets to Aid Quitting and Reduce the Risk of Dementia. | Almahasneh F et al. | — | 2024 | → |
| The association of genetic polymorphisms within the dopaminergic system with nicotine dependence: A narrative review. | Yang J et al. | — | 2024 | → |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | — | 2023 | → |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | — | 2023 | → |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | — | 2021 | → |
| Antidepressants for smoking cessation. | Howes S et al. | — | 2020 | → |
| Association of <i>COMT</i> Gene Polymorphisms with Response to Methadone Maintenance Treatment Among Chinese Opioid-Dependent Patients. | Duan L et al. | — | 2020 | → |
| Determining population stratification and subgroup effects in association studies of rare genetic variants for nicotine dependence. | Hsieh AR et al. | — | 2019 | → |
| Systematic Review of Polygenic Gene-Environment Interaction in Tobacco, Alcohol, and Cannabis Use. | Pasman JA et al. | — | 2019 | → |
| Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT. | Hall KT et al. | — | 2019 | → |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | — | 2018 | → |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | — | 2018 | → |
| Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men. | Ou WC et al. | — | 2017 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions. | Yang J et al. | — | 2016 | → |
| Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. | Patriquin MA et al. | — | 2015 | → |
| A review of pharmacogenetic studies of substance-related disorders. | Jones JD et al. | — | 2015 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2014 | → |
| Pharmacogenetics of nicotine addiction: role of dopamine. | Herman AI et al. | — | 2014 | → |
| Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. | de Viron S et al. | — | 2013 | → |
| Genomics and personalized medicine: <i>CHRNA5-CHRNA3-CHRNB4</i> and smoking cessation treatment. | Chen LS et al. | — | 2013 | → |
| Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. | David SP et al. | — | 2013 | → |
| Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability. | Hatzimanolis A et al. | — | 2013 | → |
| Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy. | Sun H et al. | — | 2012 | → |
| Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. | Leventhal AM et al. | — | 2012 | → |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | — | 2012 | → |
| Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. | McGeary JE et al. | — | 2012 | → |
| The CHRNA5-A3-B4 gene cluster in nicotine addiction. | Berrettini WH et al. | — | 2012 | → |
| Association of COMT Val(108/158)Met genotype and cigarette smoking in pregnant women. | Munafò MR et al. | — | 2011 | → |
| Biomarkers to optimize the treatment of nicotine dependence. | Schnoll RA et al. | — | 2011 | → |
| Black and White adults' perspectives on the genetics of nicotine addiction susceptibility. | Park ER et al. | — | 2011 | → |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | — | 2011 | → |
| Pharmacogenetics of antidepressant response. | Porcelli S et al. | — | 2011 | → |
| Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials. | David SP et al. | — | 2011 | → |
| [Pharmacotherapeutic treatment strategies for smoking cessation]. | Vasic N et al. | — | 2011 | → |
| Treatment for tobacco dependence: a potential application for stratified medicine? | Brock AJ et al. | — | 2011 | → |
| Are genetic variants of COMT associated with addiction? | Tammimäki AE et al. | — | 2010 | → |
| Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. | Wang J et al. | — | 2010 | → |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | — | 2010 | → |
| Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. | Fijal BA et al. | — | 2009 | → |
| Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? | Quaak M et al. | — | 2009 | → |
| Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases. | Quaak M et al. | — | 2009 | → |
| Preventing postpartum smoking relapse: an opportunity for neonatal nurses. | Forest S | — | 2009 | → |
| Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. | Schnoll RA et al. | — | 2009 | → |
| Substance use disorder genetic research: investigators and participants grapple with the ethical issues. | Coors ME et al. | — | 2009 | → |
| Variants in COMT and spontaneous smoking cessation: retrospective cohort analysis of 925 cessation events. | Breitling LP et al. | — | 2009 | → |
| Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. | Perlis RH et al. | — | 2009 | → |
| Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. | Lohoff FW et al. | — | 2008 | → |
| Association of COMT Val108/158Met genotype with smoking cessation. | Munafò MR et al. | — | 2008 | → |
| Genes and cigarette smoking. | Munafò MR et al. | — | 2008 | → |
| Genetics of nicotine dependence and pharmacotherapy. | Lessov-Schlaggar CN et al. | — | 2008 | → |
| Genetic variation in the dopamine pathway and smoking cessation. | David SP et al. | — | 2008 | → |
| Identification of pharmacogenetic markers in smoking cessation therapy. | Heitjan DF et al. | — | 2008 | → |
| Neuroimaging, genetics and the treatment of nicotine addiction. | Ray R et al. | — | 2008 | → |
| Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. | Conti DV et al. | — | 2008 | → |
| Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. | Shields AE et al. | — | 2008 | → |
| Smoking cessation in patients with psychiatric disorders. | Gelenberg AJ et al. | — | 2008 | → |
| The genetics of nicotine addiction liability: ethical and social policy implications. | Hall WD et al. | — | 2008 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2007 | → |
| Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. | Johnstone EC et al. | — | 2007 | → |
| Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study. | Ton TG et al. | — | 2007 | → |
| Genetics and smoking behavior. | Schnoll RA et al. | — | 2007 | → |
| Genetics and smoking cessation improving outcomes in smokers at risk. | Lerman CE et al. | — | 2007 | → |